Improving the Prognosis for Cerebral Hemorrhage A Study of Clinical, Biological, and Imaging Markers

This prospective, multicenter national cohort study in ICH is designed to support comprehensive clinical, biological, imaging, and process-of-care characterization of patients.

A centralized and harmonized biobank will be established to enable the collection and analysis of biological samples, with a focus on biomarkers related to inflammation, hematoma resorption, and genetic susceptibility.

A standardized and interoperable imaging database will be implemented to allow quantitative analysis of hemorrhagic lesions, including hematoma volume, hematoma expansion, perihematomal edema, and their temporal evolution over time.

The study will also document acute ICH management practices, including the proportion of patients managed according to the evidence-based care bundle validated in the INTERACT 3 study. Components of this bundle include early intensive blood pressure control, reversal of anticoagulation when applicable, maintenance of blood glucose within recommended targets, body temperature control, and systematic neurosurgical consultation. Adherence to these components will be recorded as part of routine care.

The cohort will rely on a network of participating clinical and research centers trained and equipped to apply standardized procedures for patient inclusion, data collection, imaging acquisition, and biospecimen handling, with the objective of promoting harmonized clinical practice and high-quality data generation.

Finally, the cohort is intended to serve as a structured platform to support the design and implementation of future stratified interventional clinical trials in spontaneous ICH, based on phenotypic, biomarker, imaging, and care-process data generated within the cohort.

• Proportion of patients managed according to the care bundle validated in the INTERACT 3 study, including the following components: [Срок оценки: Baseline]
• Number of stored biological samples, by sample type [Срок оценки: Through study completion, an average of ten years]
• Volume of stored biological samples, by sample type [Срок оценки: Through study completion, an average of ten years]
• Number of centralized and analyzable brain imaging studies [Срок оценки: Through study completion, an average of ten years]
• Completion rate of clinical follow-up data [Срок оценки: Through study completion, an average of ten years]
• Number of participating centers achieving a data collection quality level > 80% across the three registry components (clinical, imaging, and biological data). [Срок оценки: Through study completion, an average of ten years]
• Number of research projects initiated or scientific publications produced using data from the TIPITCH registry. [Срок оценки: Through study completion, an average of ten years]